Logo
CustomersBlogPricingDemo
SIGN UP NOWBOOK A DEMO

What is the Fiscal Year for Nuvalent?

Date: November 14, 2026


Nuvalent's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.

Current Fiscal Year Overview

Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026

Quarterly Breakdown

Q1

Jan 1, 2026 – Mar 31, 2026

Q2

Apr 1, 2026 – Jun 30, 2026

Q3

Jul 1, 2026 – Sep 30, 2026

Q4

Oct 1, 2026 – Dec 31, 2026

Company Information

Headquarters

Cambridge, Massachusetts

Industry

Biotechnology Research

Stock Symbol

NUVL

Website
https://nuvalent.com
Description

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.


Use Salesmotion for Account Data and Insights

Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Nuvalent and uncover key business information that drives smarter conversations.

Book a demo today to strengthen your sales strategy with powerful data and actionable insights.

BOOK A DEMO